Imbria Pharmaceuticals, Inc., a Boston, MA-based scientific stage biotechnology firm creating novel therapies for cardiometabolic ailments with excessive unmet want, closed a $57.5m Sequence B financing.
The spherical was led by new investor, Deep Observe Capital, with participation from AN Ventures, Catalio Capital Administration and Cytokinetics, and current traders RA Capital Administration and SV Well being Buyers.
Imbria is a scientific stage firm creating novel therapies for sufferers with life-altering cardiometabolic problems. Its scientific pipeline is concentrated on restoring or enhancing the cell’s capability to provide power in cardiometabolic problems the place energetic impairment is a basic contributor to illness pathogenesis, signs and useful deficits. The lead product candidate, ninerafaxstat, has accomplished a number of Section 2 scientific trials in three indications: non-obstructive hypertrophic cardiomyopathy (nHCM), secure angina, and coronary heart failure with preserved ejection fraction (HFpEF). In Section 1 and a pair of scientific trials, ninerafaxstat was proven to be nicely tolerated.
The corporate intends to make use of the proceeds to advance ninerafaxstat by means of a Section 2b randomized, double-blind, placebo-controlled, scientific trial in non-obstructive hypertrophic cardiomyopathy (nHCM), known as FORTITUDE-HCM, and to provoke FORTITUDE-HCM in Q2 2025, with topline knowledge in late 2026.
The corporate additionally introduced the appointment of its present Government Chair, Alvin Shih, MD to the Chief Government Officer position, plus the appointment of Rebecca Luse, Managing Director at Deep Observe Capital, to its Board of Administrators. Dr. Shih will proceed to be a member of the corporate’s Board of Administrators.
Ninerafaxstat is an progressive remedy for cardiac problems characterised by an imbalance of power provide and demand within the coronary heart. To keep up regular contractile operate, the center requires substantial quantities of power, which is produced primarily by the mitochondria within the type of adenosine triphosphate (ATP). The guts usually makes use of two principal fuels for power era: fatty acids and glucose. Ninerafaxstat, a partial fatty acid oxidation (pFOX) inhibitor, acts to shift the center’s choice from fatty acids in the direction of glucose. This shift in metabolism results in extra environment friendly mitochondrial power era with the potential for improved cardiac operate each at relaxation and through train. Ninerafaxstat is a straightforward orally administered compound with no dose titration or monitoring required, no clinically vital drug-drug interactions and can be utilized on prime of normal of care cardiovascular therapies.
FinSMEs
11/04/2025
